Skip to main content

Table 3 Comparative analysis of different viral pneumonia in immunocompromised patients

From: Characteristics of viral pneumonia in non-HIV immunocompromised and immunocompetent patients: a retrospective cohort study

Variables CMV
N = 162
IFV
N = 65
Non-IFV
N = 79
≥two viruses
N = 64
P-Value
Female, n (%) 59 (36.4) 18 (27.7) 30 (38.0) 20 (31.3) 0.509
Age, median (IQR), years 60.0 (47.0, 68.3) 63.0 (54.0, 69.0) 59.0 (47.0, 68.0) 60.0 (50.3, 67.0) 0.616
Symptoms and signs, n (%)
 Fever 138 (85.2) 48 (73.9) 48 (60.8) 42 (65.6) < 0.001
 Cough 138 (85.2) 63 (96.9) 79 (100.0) 62 (96.9) < 0.001
 Expectoration 122 (75.3) 63 (96.9) 77 (97.5) 60 (93.8) < 0.001
 Dyspnea 108 (66.7) 43 (66.2) 51 (64.6) 43 (67.2) 0.987
Underlying Diseases, n (%)
 Connective tissue disease 69 (42.6) 19 (29.2) 21 (26.6) 25 (39.1) 0.054
 Interstitial lung disease 61 (37.7) 31 (47.7) 43 (54.4) 30 (46.9) 0.084
 Diabetes mellitus 43 (26.5) 18 (27.7) 22 (27.9) 20 (31.3) 0.917
 Tumor 19 (11.7) 7 (10.8) 11 (13.9) 4 (6.3) 0.524
 Bronchial asthma 6 (3.7) 0 (0) 0 (0) 0 (0) 0.050
 COPD 13 (8.0) 6 (9.2) 3 (3.8) 2 (3.1) 0.311
 Leukemia 2 (1.2) 0 (0) 4 (5.1) 1 (1.6) 0.114
 Lymphoma 5 (3.1) 2 (3.1) 5 (6.3) 4 (6.3) 0.535
 After bone marrow or HSCT 2 (1.2) 0 (0) 1 (1.3) 2 (3.1) 0.490
 Nephrotic syndrome or chronic glomerulonephritis 36 (22.2) 2 (3.1) 4 (5.1) 4 (6.3) < 0.001
 Solid organ transplant 7 (4.3) 17 (26.2) 23 (29.1) 13 (20.3) < 0.001
 Cirrhosis 0 (0) 3 (4.6) 1 (1.3) 1 (1.6) 0.059
Laboratory examination
 White blood cell, ×109/L (IQR) 8.50 (5.70, 12.52) 7.95 (5.08, 11.07) 7.57 (5.69, 11.47) 8.50 (6.35, 11.45) 0.587
 Neutrophils, ×109/L (IQR) 7.08 (4.52, 10.94) 6.80 (3.80, 9.24) 5.69 (3.51, 8.81) 6.90 (4.86, 9.77) 0.081
 Lymphocyte, × 109/L (IQR) 0.73 (0.41, 1.40) 0.81 (0.41, 1.31) 1.11 (0.60, 1.83) 0.80 (0.45, 1.32) 0.048
 Persistent lymphocytopenia 84 (51.9) 32 (49.2) 28 (35.4) 33 (51.6) 0.097
 D-Dimer, mg/L 1.78 (0.78, 3.08) 1.52 (0.58, 3.09) 1.12 (0.55, 2.68) 1.34 (0.60, 2.57) 0.288
 Lactate dehydrogenase, U/L 395.5 (255.8, 590.0) 325.0 (228.0, 482.0) 300.0 (206.0, 430.0) 386.0 (276.0, 553.9) 0.007
 Oxygenation index 184.2 (113.5, 286.0) 285.7 (154.1375.9) 244.1 (96.3, 277.1) 122.4 (92.5, 272.8) 0.067
Severe pneumonia index score 75.0 (58.0, 107.0) 79.0 (60.0, 99.0) 79.0 (61.0, 104.0) 80.5 (57.8, 105.3) 0.508
CURB65 score > 1 55 (34.0) 25 (38.5) 19 (24.1) 18 (28.1) 0.234
Imaging features, n (%),24 missing
 Consolidation or mass 71 (43.8) 24 (36.9) 39 (49.4) 34 (53.1) 0.176
 Ground-glass opacity 99 (61.1) 30 (46.2) 42 (53.2) 35 (54.7) 0.004
Viral-PCP co-infection 64 (39.5) 4 (6.2) 3 (3.8) 7 (10.9) < 0.001
Viral-aspergillus co-infection 16 (9.9) 9 (13.8) 12 (15.2) 15 (23.4) 0.069
Viral-bacteria co-infection 22 (13.6) 7 (10.8) 10 (12.7) 9 (14.1) 0.939
Viral-atypical co-infection 6 (3.7) 1 (1.5) 3 (3.8) 1 (1.6) 0.708
Nosocomial bacterial infection 36 (22.2) 17 (26.2) 17 (21.5) 22 (34.4) 0.237
Complications, n (%)
 Noninvasive ventilation 54 (33.3) 10 (15.4) 9 (11.4) 17 (26.6) 0.001
 Invasive mechanical ventilation 45 (27.8) 20 (30.8) 16 (20.3) 19 (29.7) 0.462
 Respiratory failure 91 (56.2) 33 (50.8) 26 (32.9) 36 (56.3) 0.001
 ICU care 89 (54.9) 22 (33.8) 19 (24.1) 26 (40.6) < 0.001
 Septic shock 40 (24.7) 17 (26.2) 14 (17.7) 20 (31.3) 0.305
 Extracorporeal membrane oxygenation 4 (2.5) 7 (10.8) 7 (8.9) 6 (9.4) 0.268
 In-hospital mortality 50 (30.9) 14 (21.5) 12 (15.2) 22 (34.4) 0.022a
  1. IFV influenza A virus, influenza B virus; Non-IFV virus respiratory syncytial virus (RSV), HPIV human parainfluenza virus, HRV human rhinovirus, ADV adenovirus and HSV-1 herpes simplex virus type 1, HSCT hematopoietic stem cell transplantation, COPD Chronic obstructive pulmonary disease.
  2. aThe in-hospital mortality between non-IFV and IFV patients was not statistically different (P = 0.324), but the non-IFV group was associated with a lower in -hospital rate than that of CMV group and two or more viruses' group (P<0.05)